Anthony Letai, Director of the National Cancer Institute, shared a post on X:
“Pancreatic cancer remains a challenge. Targeting KRAS was a key step, but responses are often temporary. New National Cancer Institute supported work identifies a protein that may drive resistance, opening a path to extend treatment benefit in pancreatic and other cancers”
Other articles featuring Dr. Letai on OncoDaily.